ESTA — Establishment Labs Holdings Inc.

Establishment Labs Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $53.8 million, a 34% increase year-over-year.
• U.S. Revenue: $11.9 million, up 16% sequentially.
• Gross Profit Margin: 70.1%, the first time exceeding 70%, up from 63.9% a year ago.
• Adjusted EBITDA: Positive $1.2 million, the first positive EBITDA in company history, compared to losses of $8.5 million and $12.1 million in the previous two quarters.
• Cash Position: Increased to $70.6 million, up from $54.6 million at the end of Q2 2025.

2. Strategic Updates and Business Highlights

• U.S. Market Growth: The U.S. business is the primary growth driver, with expectations of significant acceleration in Q4. The company anticipates finishing 2025 with approximately 20% market share in the U.S. breast augmentation market.
• Product Development: The company is preparing for the U.S. launch of its breast reconstruction products and expects to file a PMA supplement by year-end.
• Minimally Invasive Portfolio: The Preserve procedure is gaining traction, with positive feedback from early adopters. The company expects this segment to contribute significantly to revenue, targeting over $30 million in 2026.
• Surgeon Engagement: Over 1,300 surgeons are now using the Motiva implants, with a strong focus on training and support to increase adoption.

3. Forward Guidance and Outlook

• 2025 Revenue Guidance: Raised to exceed $210 million, from a previous range of $208 million to $212 million, indicating at least 26% growth.
• 2026 Expectations: The company anticipates continued revenue growth of over 20% and aims to achieve cash flow positive status in 2026 without further equity raises.

4. Bad News, Challenges, or Points of Concern

• Market Dynamics: While Establishment Labs is experiencing growth, some peers in the aesthetics market are expressing caution about market dynamics, which could indicate broader industry challenges.
• International Market Stability: Although the company is seeing strong growth in direct markets, there is uncertainty regarding distributor markets, particularly in Asia-Pacific and China, where reordering timelines remain unclear.

5. Notable Q&A Insights

• Q4 Expectations: Management expressed confidence in exceeding the previously set $40 million target for Q4, although they acknowledged the challenges of navigating the first full Q4 as a company.
• International Growth: The company is optimistic about international markets, particularly in Europe and Latin America, where they expect continued strong performance.
• Surgeon Adoption Trends: Surgeons are increasingly adopting Motiva, with many reporting increased patient requests for the product, indicating a shift in consumer preference.
• Visibility on Orders: Management has good visibility on orders and customer engagement, which supports their positive outlook for Q4 and beyond.

Overall, Establishment Labs reported a strong Q3 2025, achieving significant financial milestones and positioning itself for continued growth, despite some industry-wide uncertainties.